Exicure, inc. reports full year 2021 financial results and corporate progress

Chicago--(business wire)--exicure, inc. (nasdaq: xcur), a pioneer in gene regulatory and immunotherapeutic drugs utilizing spherical nucleic acid (sna™) technology, today reported full year financial results for the quarter and year ended december 31, 2021 and provided an update on its business strategy and corporate progress. “this past year brought significant challenges to our organization that prompted strategic decisions at year-end to refocus our business strategy on our next generation p
XCUR Ratings Summary
XCUR Quant Ranking